Humanized Notch3 Antibodies for Selective Ligand Blocking
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for improved antibodies that can neutralize the biological activity of human Notch3 and be used as therapeutic agents to treat human patients, particularly for conditions such as cancer and pulmonary arterial hypertension (PAH), with a focus on enhancing affinity, specificity, stability, and reducing immunogenicity.
Innovation Solution
Development of antibodies that specifically bind human Notch3, optimized for improved biochemical properties and reduced immunogenicity, inhibiting Notch3 activation by blocking its interaction with ligands like Jag1, Jag2, and DLL4, thereby inhibiting tumor growth and treating PAH.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If naturally occurring antibodies are used, then they can be produced through standard immunization protocols, but they exhibit high immunogenicity and limited affinity when administered to human patients
Solution Approach 1:
The patent applies parameter changes by modifying the amino acid sequences of antibody CDR regions through rational design and directed evolution. Specific mutations in the CDR1, CDR2, and CDR3 regions of both heavy and light chains are introduced to optimize binding affinity to human Notch3 while reducing immunogenicity. The constant regions are also engineered to human sequences to minimize immune response.
Solution Approach 2:
The patent creates composite antibody structures by combining engineered variable regions with humanized constant regions. The chimeric and humanized antibody formats integrate non-human CDR sequences for antigen binding with human framework and constant regions, creating a composite structure that maintains high affinity while reducing immunogenicity for therapeutic use in humans.
2Reliability
If antibody affinity for Notch3 is increased through engineering, then therapeutic efficacy is improved, but the complexity of production and characterization increases
Solution Approach 1:
The patent applies preliminary action by pre-selecting and engineering antibody variants with optimized CDR sequences before production. Directed evolution and rational design are performed in vitro to generate high-affinity binders, which are then validated through binding assays and neutralization studies. This preliminary engineering reduces the need for extensive in vivo optimization and simplifies subsequent manufacturing and characterization.
3Reliability
If monoclonal antibodies are used to inhibit Notch pathway signaling, then cancer and PAH treatment potential is achieved, but off-target effects and limited specificity may occur
Solution Approach 1:
The patent applies local quality by engineering specific CDR regions to recognize unique epitopes on human Notch3 with high precision. The CDR3 regions, which provide the most significant contribution to antigen binding specificity, are carefully optimized to distinguish Notch3 from other Notch family members (Notch1, Notch2, Notch4) and to avoid binding to off-target proteins. This localized optimization of binding interface properties enhances therapeutic specificity.
Data Source
AI summary
Monoclonal antibodies that bind and inhibit activation of human Notch3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation and/or overexpression of Notch3.